Catalent Completes Acquisition of Bone Therapeutics’ Cell Therapy Manufacturing Subsidiary

Bone Therapeutics has reported the completion of Catalent’s acquisition of Skeletal Cell Therapy Support SA (SCTS)—Bone Therapeutics’ cell therapy manufacturing subsidiary—in a Nov. 16, 2020 press release.

Under the terms of the acquisition, Catalent has gained Bone Therapeutics’ SCTS for gross proceeds of €12 million (US $14.2 million). Following the completion of the acquisition, SCTS’ manufacturing infrastructure and production operating teams will be incorporated into Catalent’s Cell and Gene Therapy division. Additionally, Catalent and Bone Therapeutics have entered into associated supply agreements that will ensure continued production of ALLOB, Bone Therapeutics’ allogeneic cell therapy product, for Bone Therapeutics and its partners.

“Catalent is committed to supporting the development and manufacture of next-generation therapies and bringing life-changing treatments to patients in need,” commented Manja Boerman, president, Catalent Cell and Gene Therapy, in a press release issued by Catalent. “Following the acquisition of MaSTherCell, the additional manufacturing capacity and technical expertise that this deal with Bone Therapeutics gives us will immediately expand our functional clinical and commercial capacity for current late-stage customers. This addition also creates a strong center of cell therapy excellence for Catalent in Europe and will serve as a hub for the growing cell therapy pipeline.”

“This agreement with Catalent is an important strategic step for Bone Therapeutics and is the result of our continuous effort to optimize our operations,” added Miguel Forte, CEO, Bone Therapeutics, in the press release. “The integration of our manufacturing subsidiary into Catalent, one of the premier contract manufacturers in the cell therapy space, significantly increases our operational flexibility. It enables Bone Therapeutics to maximize the efficient use of our manufacturing assets by combining the manufacturing facility and specialist operators with Catalent’s global network of clinical and commercial manufacturing facilities. This will ensure the most efficient ongoing global production of ALLOB. It also allows us to further focus on our core activity: developing innovative cell-based treatments for conditions with high unmet medical needs. This deal will facilitate our efforts to bring ALLOB more quickly within the reach of patients around the world.”

Sources: Bone Therapeutics, Catalent